

7.2 Saran

Penelitian ini dapat digunakan sebagai dasar pengembangan ilmu dengan:

1. Melakukan penelitian lanjutan menggunakan biomarker yang sama pada kasus kanker serviks yang juga mendapatkan *brachytherapy* (radiasi intrakaviter), atau kombinasi dengan kemoterapi untuk melihat resistensi radioterapi pada kondisi instalasi radioterapi kanker serviks yang optimal (EBRT + *brachytherapy*).
2. Melakukan penelitian lanjutan dengan menggunakan biomarker yang sama pada biopsi serviks awal sebelum mendapatkan radioterapi untuk mendapatkan prediksi resistensi radioterapi.
3. Melakukan penelitian lanjutan untuk melihat enzim pembentuk PIP3 yaitu PI3K sebagai penanda / *marker* terhadap resistensi kanker serviks setelah radioterapi.

DAFTAR PUSTAKA

Ahmed, M., Fayed, S., Hossein, H. & Tash, F., 1999. Lipid peroxidation and antioxidant status in human cervical carcinoma. *Disease Markers*, 15(4), pp.283-91.

Akinleye, A. *et al.*, 2013. (PI3K) inhibitors as cancer therapeutics. *Journal of Hematology & Oncology*, 6(88).

Andrijono, 2009. *Kanker Serviks*. 2nd ed. Jakarta, Indonesia.

Bahar, I., Tjokroprawiro, B., Suhatno & Erawati, D., 2013. Radiotherapy Response of Advanced Squamous and Adenocarcinoma Types of Cervical Cancer at Dr Soetomo Hospital Surabaya. *Majalah Obstetri & Ginekologi*, 21(2), pp.48-55.

Balasubramaniyan, N., Subramanian & Govindasamy, S., 1994. Status of antioxidant systems in human carcinoma of uterine cervix. *Cancer Letters*, 87, pp.187-92.

Bandyupadhyay, U., Das, D. & Banerjee, R., 1999. Reactive oxygen species: oxidative damage and pathogenesis. *Curr Sci*, 77(5).

Barrera, G., 2012. Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy. *International Scholarly Research Network*, 2012, pp.1-21.

Benedet, J., Odicino, F. & Maisonneuve, P., 2003. Carcinoma of the cervix uteri. *Journal of Gynaecology Obstetrics*, 1, pp.41-78.

Berek, J., 2007. *Berek & Novak's Gynecology*. 14th ed. California: Lippincott Williams & Wilkins.

Berek, J. & Hacker, N., 2005. *Practical gynecologic oncology*. 4th ed. Philadelphia: Lippincott williams and wilkins.

Bergman, P. & Harris, D., 1997. Radioresistance, Chemoresistance, and Apoptosis Resistance. *Radiation Oncology*, 27(1), pp.47-57.

Bhosle, S., Huilgol, N. & Mishra, K., 2005. Apoptotic index as predictive marker for radiosensitivity of cervical carcinoma: Evaluation of membrane fluidity, biochemical parameters and apoptosis after the first dose of fractionated radiotherapy to patient. *Cancer Detection and Prevention*, 29, pp.369-75.

Bhuvarahamurthy, V., Balasubramanian, N. & Govindasamy, S., 1996. Effect of radiotherapu and chemoradiotherapu on circulating antioxidant system of human uterine cervical carcinoma. *Molecular and Cellular Biochemistry*, 158, pp.17-23.

Bisht, K. et al., 2003. Geldanamycin and 18-Allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radioation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. *The Journal of Cancer Research*, 63, pp.8984-95.

Bonfrer, J. et al., 1994. Prognostic Significance of Serum Fragments of Cytokeratin 19 Measured by Cyfra 21-1 in Cervical Cancer. *Gynecologic Oncology*, 55, pp.371-75.

Bravard, A. et al., 2002. Correlation between antioxidant status, tumorigenicity and radiosensitivity in sister rat cell lines. *Carcinogenesis*, 23(5), pp.705-11.

Carrilho, C., Alberto, M., Buane, L. & David, L., 2004. Keratins 8, 10, 13, and 17 are useful markers in the diagnosis of human cervix carcinomas. *Human Pathology*, 35(5), pp.546-51.

Chang, C. et al., 2005. Radioimmunotherapy and Apoptotic Induction on Ck19overexpressing Human Cervical Carcinoma Cells with Re-188-mAbCx-99. *Anticancer Research*, 25, pp.2719-28.

Ciocca, D. & Calderwood, S., 2005. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. *Cell Stress & Chaperones*, 10(2), pp.86-103.

Divisi Onkologi Ginekologi, 2014. *Data Kanker Serviks Poli Onkologi Ginekologi*. Surabaya: Universitas Airlangga.

Dui, X. et al., 2009. Silencing of heat shock protein 70 expression enhance. *Croat Med J*, 50, pp.143-50.

Du, X. et al., 2009. Silencing of heat shock protein 70 expression enhances radiotherapy efficacy and inhibits cell invasion in endometrial cancer cell line. *Croatian Medical Journal*, 50(2), pp.143-50.

Engelman, J., Luo, J. & LC, C., 2006. The evolution of phosphatidylinositol 3 kinase as regulators of growth and metabolism. *Nature Reviews. Genetics*, 7, pp.606-19.

Ferlay, J., Shin, H. & Bray, F., 2010. *Cancer incidence and mortality worldwide*. Lyon: GLOBOCAN IARC.

Fujiyoshi, N. *et al.*, 2015. Radiation effects on DNA content of cervical cancer cells: A rapid evaluation f radiation sensitivity by laser scanning cytometry. *Molecular and Clinical Oncology*, 3, pp.51-54.

Fulda, S., 2013. Regulation of cell death in cancer-possible implications for immunotherapy. *Frontiers in Oncology*, 3(29), pp.1-5.

Garrido, C. *et al.*, 2003. HSP27 and HSP70: Potentially Oncogenic Apoptosis Inhibitors. *Cell Cycle*, 2(6), pp.579-84.

Gehrman, M., Radons, J., Molls, M. & Multhoff, G., 2008. The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells. *Cell Stress and Chaperones*, 13, pp.1-10.

Gehrman, M. *et al.*, 2014. Hsp70 - a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. *Radiatioon Oncology*, 9(131), pp.1-9.

Gunalan, G. & Krishnamurthy, V., 2012. Impact of radiotherapy on oxidative stress in neutrophils of cervical cancer patients. *Asian Journal of pharmaceutical and clinical research*, 5(2).

Hancock, J., Desikan, R. & Neill, S., 2001. Role of reactive oxygen species in cell signalling pathways. *Biochemical Society Transactions*, 29(2).

Han, K. *et al.*, 2013. Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States. *International Journal of Radiation Oncology Biology Phisics*, 87(1), pp.111-19.

- Hogg, R., Hay, S. & Kirk, J., 20091. *Best clinical practice: Gynaecological cancer guidelines*. Jakarta: GMCT.
- Javvadi, P., Segan, A., Tuttle, S. & Koumenis, C., 2008. The Chemopreventive Agent Curcumin Is a Potent Radiosensitizer of Human Cervical Tumor Cells via Increased Reactive Oxygen Species Production and Overactivation of the Mitogen-Activated Protein Kinase Pathway. *Molecular Pharmacology*, 73, pp.1491-501.
- Jiang, B. & Liu, L., 2008. PI3K/PTEN signaling in tumorigenesis and angiogenesis. *Biochimica et Biophysica Acta*, 1784(1), pp.150-8.
- Jyoti, S.N.S., Biharilal, S. & Achala, S., 2009. Study of blood levels of antioxidant enzymes and erythrocyte malondialdehyde (MDA) in ovarian, cervical and uterine cancer at stage I. *Journal of Obstetric Gynecology India*, 59(3), pp.242-5.
- Kainz, C. *et al.*, 1995. Cytokeratin Subunit 19 Measured by CYFRA 21-1 Assay in Follow-up of Cervical Cancer. *Gynecologic Oncology*, 56, pp.402-05.
- Kaur, P., Hurwitz, M., Krishnan, S. & Asea, A., 2011. Combined Hyperthermia and Radiotherapy for the Treatment of Cancer. *Cancers*, 3, pp.3799-823.
- Kevin, A., Camphausen & Lawrence, R., 2009. *Principles of radiation therapy*.
- Kim, T. *et al.*, 2006. Increased Expression of pAKT is associated with radiation resistance in cervical cancer. *British Journal of Cancer*, 94, pp.1678-82.
- Krasilnikov, M. *et al.*, 1999. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. *Molecular Carcinogenesis*, 24(1), pp.64-9.

Lee, J., Chang, K., Han, J. & Ryu, H., 2005. Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors. *International Journal of Gynecologic Cancer*, 15, pp.113-19.

Lehnert, S., 2007. *Biomolecular action of ionizing radiation*. New York: CRC Press.

Liu, P., Cheng, H., Roberts, T. & Zhao, J., 2009. Targeting the phosphoinositide 3 kinase pathway in cancer. *Nature Reviews. Drug Discovery*, 8, pp.627-44.

Liu, Q. et al., 2014. 2014. *Neuro-oncology*, pp.1-11.

Manju, C., Balasubramanian, V. & Nalini, N., 2002. Oxidative stress and tumor markers in cervical cancer patients. *Journal of Biochemistry, Molecular Biology and Biophysics*, 6(6), pp.387-90.

Manoharani, S., Kolanjiappani, K. & Kayalvizhiz, M., 2004. Enhanced lipid peroxidation and impaired enzymic antioxidant activities in the erythrocytes of patients with cervical carcinoma. *Cellular & molecular biology letters*, 9, pp.699-707.

Marklund, S., Westman, N., Lundgren, E. & Roos, G., 1982. Copper- and Zinc-containing Superoxide Dismutase, Manganese-containing Superoxide Dismutase, Catalase, and Glutathione Peroxidase in Normal and Neoplastic Human Cell Lines and Normal Human Tissues. *Cancer Research*, 42, pp.1955-61.

Mol, R., M, D. & Langbein, L., 2008. the human keratins: biology and pathology. *Biochem Cell Biol*, 129, pp.705-33.

Mukherjee, G. et al., 2001. Biologic factors and response to radiotherapy in carcinoma of the cervix. *International Journal of Gynecologic Cancer*, 11, pp.187-93.

Multhoff, G. et al., 1995. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. *International Journal of Cancer*, 61, pp.272-79.

Murphy, M., 2013. The HSP70 family and cancer. *Carcinogenesis*, 34(6), pp.1181-88.

Nakano, T. et al., 2005. Long-Term Results of High-Dose Rate Intracavitary Brachytherapy for Squamous Cell Carcinoma of the Uterine Cervix. *Cancer*, 103(1), pp.92-101.

Ohno, T. et al., 1998. Bax Protein Expression Correlates with Radiation-Induced Apoptosis in Radiation Therapy for Cervical Carcinoma. *Cancer*, 83(1), pp.103-10.

Osaki, M., Oshimura, M. & Ito, H., 2004. PI3K-Akt pathway: Its functions and alterations in human cancer. *Apoptosis*, 9(6), pp.667-76.

Ota, T. et al., 2007. Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers. *British Journal of Cancer*, 97(8), pp.1058-62.

Pajonk, F., Vlashi, E. & McBride, W., 2010. Radiation Resistance of Cancer Stem Cells: The 4 R's of Radiobiology Revisited. *Stem Cells*, 28(4), pp.639-48.

Park, C. *et al.*, 1999. An Immunohistochemical Analysis of Heat Shock Protein 70, p53, and Estrogen Receptor Status in Carcinoma of the Uterine Cervix. *Gynecologic Oncology*, 74, pp.53-60.

Parrino, J., Hotchkiss, R. & Bray, M., 2007. Prevention of immune cell apoptosis as potential therapeutic strategy: mechanism and regulation of apoptosis. *Emerging Infectious Diseases*, 13(2), pp.191-8.

Powell, M., 2010. Modern Radiotherapy and Cervical cancer. *International Journal of Gynecologic Cancer*, 20, pp.549-51.

Pras, E. *et al.*, 2002. Serum Squamous Cell Carcinoma Antigen and CYFRA 21-1 in Cervical Cancer Treatment. *International Journal of Radiation Oncology Biology Physics*, 52(1), pp.23-32.

Rastogi, P. & Sinha, R., 2009. Apoptosis: molecular mechanism and pathogenicity. *Experimental and Clinical Sciences Journal*, 8, pp.155-81.

Reed, J., 2000. Mechanism of apoptosis. *Am J Pathol*, 157(5).

Roche, 2004. *Apoptosis, cell death and cell proliferation*. 3rd ed. Roche applied science.

Rock, J. & Jones, H., 2008. *Te Linde's Operative Gynecology*. 10th ed. Lippincott Williams & Wilkins.

Rupnow, B. & Knox, S., 1999. The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. *Apoptosis*, 4, pp.115-43.

Schmitt, E., Gehrmann, M. & Brunet, M., 2007. Intracellular and extracellular functions of heat shock protein. *Germany journal of leukocyte biology*, 81.

Schorge, J., Schaffer, J. & Halvorson, L., 2008. *Williams gynecology*. New York: McGraw-hills company.

Sherman, M. & Multhoff, G., 2004. *Heat shock protein in cancer*. Munich: Department of radiotherapy.

Smith, J., Healy, J. & Priore, G., 2008. *Atlas of staging in gynecological cancer*. London: Springer-veerlag London limited.

Sreedhar, A. & Sermely, P., 2004. Heat shock protein in the regulation of apoptosis: new strategies in tumor therapy. *Journal of Pharmacology Pharmacotherapeutics*, 101, pp.227-57.

Suzuki, Y. et al., 2000. serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. *Journal of Cancer Research and Clinical Oncology*, 126(6), pp.332-6.

Tokunaga, E. et al., 2008. Deregulation of the Akt Pathway in Human Cancer. *Current Cancer Drug Targets*, 8(1), pp.27-36.

Ummer, S. & Das, A., 2012. Biomarkers For Therapeutic Response in Cervical Cancer. *International Journal of Pharmaceutical Sciences and Research*, 3(9), pp.3036-44.

Van Bommel, F. et al., 1994. expression of cytokeratin 10, 13 and involucrin as prognostic factors in low stage squamous cell carcinoma of the uterine cervix. *Cancer*, 74(8), pp.2314-20.

Wang, H. *et al.*, 2006. Micrometastases detected by cytokeratin 19 expression in sentinel lymph nodes of patients with early-stage cervical cancer. *International Journal of Gynecologic Cancer*, 16, pp.643-48.

West, C. & Barnett, G., 2011. Genetics and genomics of radiotherapy toxicity towards prediction. *West and Barnett Genome Medicine*, 3, p.52.

West, C., Davidson, S., Burt, P. & Hunter, R., 1995. The Intrinsic Radiosensitivity of Cervical Carcinoma: Correlations with Clinical Data. *International Journal of Radiation Oncology Biology Physics*, 31(4), pp.841-46.

West, C., Davidson, S., Roberts, S. & Hunter, R., 1997. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. *British Journal of Cancer*, 78(9), pp.1184-90.

Wiedok, N., 2013. *Modulation of radiosensitivity of human tumor and normal cells by inhibition of heat shock protein Hsp90 and Hsp70*. PhD Thesis. Warsaw: Universitat Wurzburg.
Wootipoom, V. *et al.*, 2004. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. *Gynecologic Oncology*, 94, pp.636-42.

World Health Organization, 2014. Human Papillomavirus Vaccines: WHO position paper. *Weekly epidemiological record*, 43(89), pp.465-92.

Wu, J., Chen, C. & Zhao, K., 2013. Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer. *Current Cancer Drug Targets*, 13(2), pp.1-14.